Skip to main content
Premium Trial:

Request an Annual Quote

Bruker's Non-Affiliated Shareholders Approve BioSpin Buy, Name Change

NEW YORK (GenomeWeb News) – Bruker BioSciences today said that its non-affiliated stockholders have approved the acquisition of Bruker BioSpin.
 
Bruker’s $914 million acquisition of sister company BioSpin cleared the US antitrust period last month. BioSpin is 100 percent owned by members of the Laukien family, who also own 52 percent of Bruker BioSciences. Following completion of the deal, the combined firm will be renamed Bruker Corporation and 60 percent of its shares will be held by the Laukien family.
 
In addition to approving the acquisition, shareholders approved amendments to the firm’s certificate of incorporation including the name change.
 
The firm also said today that Tony Keller, executive chairman and former CEO of BioSpin, and Dirk Laukien, president of Bruker Optics, were elected to serve on Bruker’s board of directors.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.